Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Bibliographic Details
Title:	Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Authors:	Trent, Jonathan C., Wagner, Andrew J., Attia, Steven, Agulnik, Mark, Wilky, Breelyn A., Tap, William D., von Mehren, Margaret, Davis, Elizabeth J., Zou, Liangxing, Shah, Nisha, Moynihan, Kevin, Lawrence, Julia, Sun, Lei, Somaiah, Neeta
Source:	Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p826-826, 47p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2025.43.4_suppl.826
Published in:	Journal of Clinical Oncology
Language:	English